Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.

Liu Y, Zhou S, Wan Y, Wu A, Palmisano M.

Br J Clin Pharmacol. 2014 Nov;78(5):1050-7. doi: 10.1111/bcp.12448.

2.

Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.

Noh YH, Lim HS, Jin SJ, Kim MJ, Kim YH, Sung HR, Choi HY, Bae KS.

Clin Ther. 2012 May;34(5):1182-94. doi: 10.1016/j.clinthera.2012.04.001. Epub 2012 Apr 24.

PMID:
22534255
3.

The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study.

Shin KH, Kim BH, Kim TE, Kim JW, Yi S, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS.

Clin Ther. 2009 Dec;31(12):3009-20. doi: 10.1016/j.clinthera.2009.12.012.

PMID:
20110038
4.
5.

Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.

Boinpally R, Gad N, Gupta S, Periclou A.

Clin Ther. 2014 Nov 1;36(11):1638-49. doi: 10.1016/j.clinthera.2014.08.003. Epub 2014 Sep 16.

PMID:
25236915
6.

Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives.

Calcagnile S, Lanzarotti C, Rossi G, Henriksson A, Kammerer KP, Timmer W.

Support Care Cancer. 2013 Oct;21(10):2879-87. doi: 10.1007/s00520-013-1857-9. Epub 2013 Jun 11.

PMID:
23748441
7.

The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers.

Garg V, Chandorkar G, Yang Y, Adda N, McNair L, Alves K, Smith F, van Heeswijk RP.

Br J Clin Pharmacol. 2013 Feb;75(2):431-9. doi: 10.1111/j.1365-2125.2012.04345.x.

8.

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.

Shoaf SE, Bricmont P, Mallikaarjun S.

Br J Clin Pharmacol. 2012 Apr;73(4):579-87. doi: 10.1111/j.1365-2125.2011.04114.x.

9.

Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.

Lassen U, Miller WH, Hotte S, Evans TR, Kollmansberger C, Adamson D, Nielsen DL, Spicer J, Chen E, Meyer T, Brown K, Rafi R, Sawyer MB.

Cancer Chemother Pharmacol. 2013 Feb;71(2):543-9. doi: 10.1007/s00280-012-2038-0. Epub 2012 Nov 30.

PMID:
23196640
10.
11.

Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.

Hoffmann M, Kumar G, Schafer P, Cedzik D, Capone L, Fong KL, Gu Z, Heller D, Feng H, Surapaneni S, Laskin O, Wu A.

Xenobiotica. 2011 Dec;41(12):1063-75. doi: 10.3109/00498254.2011.604745. Epub 2011 Aug 23.

12.

Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.

Kerbusch T, Jansen RL, Mathôt RA, Huitema AD, Jansen M, van Rijswijk RE, Beijnen JH.

Clin Pharmacol Ther. 2001 Aug;70(2):132-41.

PMID:
11503007
13.

Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.

Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, Kowalski D, Roy M, Marion A, Takusagawa S, van Gelderen M, Keirns J.

Clin Drug Investig. 2013 Jun;33(6):429-40. doi: 10.1007/s40261-013-0084-y.

PMID:
23625188
14.

Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.

Shumaker RC, Aluri J, Fan J, Martinez G, Thompson GA, Ren M.

Clin Drug Investig. 2014 Sep;34(9):651-9. doi: 10.1007/s40261-014-0217-y.

15.

Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.

Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T.

Drugs R D. 2011;11(1):37-51. doi: 10.2165/11586980-000000000-00000.

16.

Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma.

Hellmann A, Rule S, Walewski J, Shpilberg O, Feng H, van de Velde H, Patel H, Skee DM, Girgis S, Louw VJ.

Clin Pharmacokinet. 2011 Dec 1;50(12):781-91. doi: 10.2165/11594410-000000000-00000.

PMID:
22087865
17.

Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers.

Shaik MN, LaBadie RR, Rudin D, Levin WJ.

Cancer Chemother Pharmacol. 2014 Aug;74(2):411-8. doi: 10.1007/s00280-014-2502-0. Epub 2014 Jun 19.

PMID:
24944041
18.

Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study.

Harrison B, Magee MH, Mandagere A, Walker G, Dufton C, Henderson LS, Boinpally R.

Clin Drug Investig. 2010;30(12):875-885. doi: 10.2165/11539110-000000000-00000.

PMID:
20923245
19.

The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.

Shi JG, Chen X, Emm T, Scherle PA, McGee RF, Lo Y, Landman RR, McKeever EG Jr, Punwani NG, Williams WV, Yeleswaram S.

J Clin Pharmacol. 2012 Jun;52(6):809-18. doi: 10.1177/0091270011405663. Epub 2011 May 20.

PMID:
21602517
20.

The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.

Stroh M, Palcza J, McCrea J, Marsilio S, Breidinger S, Panebianco D, Johnson-Levonas A, Kraft WK, Orford K, Murphy G, Agrawal N, Trucksis M, Wagner JA, Iwamoto M.

Cancer Chemother Pharmacol. 2012 May;69(5):1247-53. doi: 10.1007/s00280-011-1819-1.

PMID:
22290273

Supplemental Content

Support Center